プロセス開発と最適化
技術範囲、品質レベル、バッチ文書、納品要件はプロジェクトの段階に応じて設定できます。
生物学研究および産業用途を目的としており、個人の臨床用途または医療用途を意図したものではありません。
初期の技術評価からスケールアップ、安定供給までを一貫して支える統合型ペプチド CDMO サービス。
中核技術
パイロット・GMP 製造の調整
技術範囲、品質レベル、バッチ文書、納品要件はプロジェクトの段階に応じて設定できます。
不純物戦略とバッチ出荷判定の支援
技術範囲、品質レベル、バッチ文書、納品要件はプロジェクトの段階に応じて設定できます。
製薬パートナー向けのカスタムプロジェクト管理
技術範囲、品質レベル、バッチ文書、納品要件はプロジェクトの段階に応じて設定できます。
標準的な流れ
1要件確認
2技術的実現性
3見積とスケジュール
4合成またはプロセス実行
5QC 文書
6出荷とフォローアップ
| 開発段階 | ペプチドサポート |
|---|---|
| コンセプトと実現性 | ペプチド設計戦略、配列最適化、実現性評価 |
| 探索研究 | カスタムペプチド合成、ターゲティングペプチド設計、機能スクリーニング支援 |
| リード最適化 | ペプチド修飾、コンジュゲーション戦略、構造活性最適化 |
| プロセス開発 | 合成ルート最適化、プロセス頑健性、不純物管理戦略 |
| GMP 製造 | GMP 準拠のペプチド合成、品質文書、バッチ出荷判定の支援 |
技術ノート
Where the cost sits at scale
At milligram scale, cost is dominated by labour and turnaround. At kilogram scale it shifts to raw materials, solvent volume and waste handling. That reversal is why a route optimised for speed at small scale is often the wrong route at large scale: an expensive coupling reagent that saves an afternoon is immaterial in a screening batch and significant in a campaign. Route selection for a commercial process is therefore made against the intended scale, not the current one.
Stepwise synthesis versus fragment condensation
In stepwise synthesis every cycle multiplies into the overall yield, so long sequences lose material rapidly even at high per-step efficiency. Fragment condensation builds and purifies shorter pieces separately and joins them, which allows failures to be removed before the final assembly and improves overall yield for long targets. It adds the problem of joining the fragments cleanly, including control of racemisation at the junction, so the choice is made per sequence.
Purification at scale
Preparative chromatography usually dominates both the cost and the solvent footprint of a peptide process. The levers are loading, gradient design, and how the collected fractions are pooled, all of which trade recovery against purity. Reworking off-specification fractions can recover material but adds cycle time and its own impurity considerations. These decisions are made deliberately during development, since they set the economics of every batch afterwards.
In-process controls
Controls exist to catch a problem while it can still be fixed, not to document it afterwards. In peptide manufacture that typically means monitoring coupling completion before proceeding, checking cleavage and deprotection are complete, and confirming the crude profile before committing material to purification. Where a control sits and what it triggers is part of process design, because a control with no defined action attached to it is only paperwork.
Change control after transfer
Once a process is established, changes to it need to be assessed for their effect on the product rather than applied because they are locally convenient. A different supplier for a protected amino acid, a modified purification gradient or a new column lot can all shift the impurity profile. Controlled change is what keeps material made next year comparable to material made this year, which is the entire basis of a long-term supply arrangement.
納品物
- Route assessment covering yield, impurity profile and scalability
- Developed process description at the agreed scale
- Analytical methods matched to the impurities the process produces
- Technology transfer documentation including critical parameters
- Manufactured batches against the agreed specification
主な用途
Taking a route from laboratory to production — Where a sequence has been made successfully at small scale and the question is whether that route survives scale-up, or whether a different one is needed.
Improving an existing process — Reducing cost, solvent consumption or cycle time on a process already in use, with the impurity profile kept comparable throughout.
Second-source and dual-supply setup — Establishing an alternative manufacturing route for a peptide already supplied elsewhere, including comparability against the incumbent.
Scale-dependent feasibility — Assessing before committing whether a target is realistic at the intended scale and cost, including the case where the answer is that it is not.
よくあるご質問
What is the difference between a CDMO and a custom synthesis supplier?
Custom synthesis delivers a quantity of material. A CDMO engagement takes on the process: developing it, transferring it, and manufacturing to it repeatedly under a quality framework. If you need material once, custom synthesis is the right route. If you need the same material reproducibly for years, the process itself is the deliverable.
What do you need to assess a project?
The sequence and any modifications, the intended scale and how it is expected to grow, the required quality level and regulatory pathway, and any existing process and analytical data. Prior data is particularly valuable, including data from batches that failed, since it usually indicates where the difficulty is.
Can you take over a process developed elsewhere?
Yes. Transfer works best with the full package: process description, analytical methods, specifications, and the batch history that shows how the process behaves in practice. Where documentation is incomplete, part of the work is re-establishing what the critical parameters actually are before scaling anything.
How is scale-up risk managed?
By identifying which parameters the process is sensitive to before changing scale, and by scaling in steps rather than in one move. The steps most likely to behave differently are those where mixing, heat transfer or reaction time change materially with vessel size, and those are the ones examined first.
Does the impurity profile change with scale?
Frequently, yes, and that is why analytical work runs alongside scale-up rather than after it. Longer processing times, different mixing and revised purification loading can all shift which impurities appear and in what proportion. Detecting that shift early is what keeps a specification from being written against a process that no longer exists.
How early should a CDMO be involved?
Earlier than is typical. Decisions taken during discovery, such as which unnatural residues or modifications a sequence contains, can determine whether it is manufacturable at scale at all. Reviewing that while the sequence can still be changed is considerably cheaper than discovering it once the sequence is fixed.
関連ペプチド製品
単一ペプチド
単一ペプチド製品の全カタログをご覧いただけます。見積は問い合わせベースです。
続きを読むDSIP（5 mg バイアル）
DSIP（5 mg バイアル）：研究機関向けの溶解リファレンスです。希釈液量と得られる濃度、シリンジ単位への換算、バイアルおよび消耗品の計画、保管に関する指針を含みます。
続きを読むGHK-Cu（50 mg バイアル）
凍結乾燥品として供給される GHK-Cu（50 mg バイアル） の取り扱いに関する注意事項です。溶解液量と得られる濃度、U-100 シリンジ単位への換算、プロトコルごとの消耗品数、保管条件を扱います。
続きを読むIpamorelin（5 mg バイアル）
Ipamorelin（5 mg バイアル）：研究機関向けの溶解リファレンスです。希釈液量と得られる濃度、シリンジ単位への換算、バイアルおよび消耗品の計画、保管に関する指針を含みます。
続きを読む